Information  X 
Enter a valid email address

Accrol Group Hldgs (ACRL)

  Print   

Thursday 14 January, 2021

Accrol Group Hldgs

PDMR Dealings

RNS Number : 6151L
Accrol Group Holdings PLC
14 January 2021
 

14 January 2021

 

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

Accrol Group Holdings plc

(the "Company")

AIM: ACRL

 

PDMR Dealings

 

Accrol Group Holdings plc, a leading independent tissue converter in the UK, announces that as a result of the Company releasing its half-year results for the six months ended 31 October 2020, certain shares held by PDMRs have ceased to be locked in and as a result the following PDMR dealings have occurred.

 

PDMR  

Number of ordinary shares held pre dealing

Number of ordinary shares sold  

Number of ordinary shares held post dealing

% of issued share capital held post dealing






Gareth Jenkins

5,598,632

1,333,000

4,265,632

1.37%

Mark Dewhurst

1,489,975

444,000

1,045,975

0.34%

Graham Cox

683,970

333,000

350,970

0.11%

 

Further details of the PDMR dealings are included below.

 

For further information, please contact:




Accrol Group Holdings plc


Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer




Zeus Capital Limited (Nominated Adviser & Broker) 


Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000



Liberum Capital Limited (Joint Broker)

Tel: +44 (0) 20 3100 2222

Clayton Bush / Edward Thomas




Belvedere Communications Limited


Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525

Llew Angus

Tel:  +44 (0) 7407 023 147


[email protected]

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls and facial tissues to many of the UK's leading discounters and grocery retailers across the UK. Following the recent acquisition of a state-of-the-art tissue converter based in Leicester, the Group now operates from five sites, including four in Lancashire, which generate revenues totalling c.16% of the £1.7bn UK retail tissue market.

 

For more information, please visit www.accrol.com .

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 


1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Gareth Jenkins

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.001 each

 

 

 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Sale of shares



c)

Price(s) and volume(s)

Price: £0.705

Volume: 1,333,000

d)

Aggregated information

- Aggregated volume

- Price

Price: £0.705

Volume: 1,333,000

e)

Date of the transaction

13 January 2021

f)

Place of the transaction

London Stock Exchange, AIM

 


1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mark Dewhurst

2

Reason for the notification

a)

Position/status

Chief Operating Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.001 each

 

 

 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Sale of shares



c)

Price(s) and volume(s)

Price: £0.705

Volume: 444,000

d)

Aggregated information

- Aggregated volume

- Price

Price: £0.705

Volume: 444,000

e)

Date of the transaction

13 January 2021

f)

Place of the transaction

London Stock Exchange, AIM

 


1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Graham Cox

2

Reason for the notification

a)

Position/status

Commercial Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.001 each

 

 

 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Sale of shares



c)

Price(s) and volume(s)

Price: £0.705

Volume: 333,000

d)

Aggregated information

- Aggregated volume

- Price

Price: £0.705

Volume: 333,000

e)

Date of the transaction

13 January 2021

f)

Place of the transaction

London Stock Exchange, AIM

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUOSBRARUAAAR

a d v e r t i s e m e n t